Aim: Outcomes of first-line treatment (Tx) for patients ( pts) with metastatic poor prognosis GCT are still suboptimal in literature. However, the low incidence of disease and the increasing effectiveness of salvage therapy are issues against further clinical research in the field. We conducted a retrospective study to evaluate the impact of Tx period on prognosis of pts referred to our tertiary cancer center. Methods: A retrospective analysis was conducted on pts receiving at least first-line chemotherapy (CT) at our center. Distribution of frequencies of clinical characteristics were evaluated in the periods <1997, 1997-2001, 2001-06, and 2007-13. The Kaplan-Meier method was used to estimate progression-free (PFS) and overall survival (OS). PFS and OS were calculated since the start of first-line CT. Tx period was included in univariable (UVA) and multivariable (MVA) Cox regression models for PFS and OS together with the following variables: tumor primary, liver-bone-brain (LBB) metastases, first-line PEB vs high-dose CT (HDCT), AFP>1000 IU/ml, HCG > 1000 IU/l. All tests and confidence intervals were two-sided and set at p = 0.05 level of significance. Conclusions: In this single-center series of poor prognosis GCT we could not demonstrate an effect on Tx period on survival. The slight differences in PFS on UVA are likely due to modest discrepancies in distribution of clinical variables (LBB). The global picture is that of a stable and very high cure-rate. Based on these results, attempts to improve the outcome exclusively in this field should be discouraged. Results are biased by their retrospective quality. Disclosure: All authors have declared no conflicts of interest.
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